Jeffrey S Simon

Summary

Publications

  1. ncbi request reprint Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
    Jeffrey S Simon
    Northbrooke Research Center, 9275 North 49th Street, Suite 200, Brown Deer, WI 53223, USA
    J Psychiatr Res 38:249-57. 2004
  2. ncbi request reprint Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder
    Jeffrey S Simon
    Northbrooke Research Center, Brown Deer, WI 53223, USA
    J Clin Psychiatry 66:1216-20. 2005
  3. doi request reprint The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    J Clin Psychopharmacol 28:156-65. 2008

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
    Jeffrey S Simon
    Northbrooke Research Center, 9275 North 49th Street, Suite 200, Brown Deer, WI 53223, USA
    J Psychiatr Res 38:249-57. 2004
    ..Cumulative relapse rates at 3 and 6 months were 19 and 28%, respectively, for venlafaxine XR, and 44 and 52%, respectively, for placebo. This study demonstrates that venlafaxine XR is an effective and safe continuation therapy...
  2. ncbi request reprint Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder
    Jeffrey S Simon
    Northbrooke Research Center, Brown Deer, WI 53223, USA
    J Clin Psychiatry 66:1216-20. 2005
    ..To determine the efficacy and tolerability of aripiprazole, a dopamine D2 and 5-HT1A receptor partial agonist, as augmentation of antidepressant treatment of partially responding and nonresponding patients with major depressive disorder...
  3. doi request reprint The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    J Clin Psychopharmacol 28:156-65. 2008
    ..1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT...